Related by context. All words. (Click for frequent words.) 69 relapsed Acute Myeloid 68 SPRYCEL ® 66 Cutaneous T 66 Hormone Refractory Prostate Cancer 65 indolent follicular non 65 relapsed MM 65 dasatinib Sprycel ® 65 metastatic ocular 65 TO AVOID PREGNANCY WHILE 65 refractory cutaneous T 65 myocardial infarction ventricular fibrillation 64 Oral Fingolimod 64 hypertrichosis occurred 64 ACTEMRA TM 64 opioid naive 64 Leukemia AML 64 5 FU leucovorin 64 Follicular Lymphoma 64 Meets Primary Endpoint 63 Demonstrates Positive 63 Recurrent Glioblastoma 63 Amgen Neulasta R 63 Complicated Skin 63 Relapsed Refractory 63 FEMALES SHOULD BE ADVISED 63 metastatic GIST 63 recurrent metastatic ovarian cancer 63 CYT# potent vascular disrupting 63 refractory NSCLC 63 carcinoma mCRC 62 pan histone deacetylase 62 Patients Receiving 62 cisplatin gemcitabine 62 Adjuvant Treatment 62 Study Shows Promise 62 acute GvHD 62 R ferumoxytol Injection 62 Randomized Phase II 62 Fludarabine 62 included exfoliative dermatitis 62 refractory chronic lymphocytic 62 See CONTRAINDICATIONS 62 Relapsed 62 Acute Myeloid Leukemia AML 62 Plaque Psoriasis 62 Combination REOLYSIN R 62 HER2 Positive Breast Cancer 62 alfa 2a 62 Shows Efficacy 62 Mg Usa 61 Acute Exacerbations 61 Diffuse Large B 61 Adjunctive Therapy 61 Relapsed Multiple Myeloma 61 Bayer HealthCare Onyx Pharmaceuticals 61 Malignant Glioma 61 Improves Outcomes 61 modified glutathione analog 61 ® lenalidomide 61 receiving chemoradiation therapy 61 First Patient Enrolled 61 irinotecan containing 61 Refractory Hodgkin Lymphoma 61 monoclonal antibody IgG1 Mab 61 NCCN Updates 61 Node Positive 61 Advanced Melanoma 61 paclitaxel Taxol R 61 forodesine purine nucleoside phosphorylase 61 Initiate Phase III 61 essential thrombocythemia ET 61 sorafenib tablets 61 Relapsing Remitting Multiple Sclerosis 61 Chronic Myeloid Leukemia 61 systemic anaplastic large 61 Castration Resistant Prostate Cancer 61 refractory chronic myeloid 61 Degarelix 61 humanized interleukin 6 61 IN PATIENTS WITH 60 novel VDA molecule 60 Frozen Shoulder syndrome Adhesive 60 leukemia AML 60 nilotinib Tasigna ® 60 evaluating picoplatin 60 Improves Survival 60 brand ciclesonide HFA 60 inflammatory PDE 60 clinical trials Archexin 60 castration resistant hormone refractory 60 Paraplatin ® 60 unresectable Stage III 60 5 fluorouracil leucovorin 60 gastrointestinal stromal tumors GIST 60 Relapsing Multiple Sclerosis 60 cell lymphoma CTCL 60 stage IIIb IV 60 Chronic Sinusitis 60 Hsp# Inhibitor 60 cutaneous T 60 pralatrexate injection folate analogue 60 FUSILEV enhances 60 Renal Cell Carcinoma 60 Rheumatoid Arthritis Patients 60 acute peptic ulcer 60 registrational Phase 60 Metastatic Prostate Cancer 60 d l leucovorin 60 R Saizen R 60 dependent kinase inhibitor 60 Pivotal Phase 60 Xeloda ® 60 de novo kidney transplant 60 Rare Genetic 60 blinded randomized placebo controlled 60 CG# oncolytic virus 60 Newly Diagnosed Multiple Myeloma 60 Previously Treated 60 AN# topical anti 60 Pooled Analysis 60 refractory indolent non 60 Follicular lymphoma 60 aflibercept VEGF Trap 60 relapsing remitting MS RRMS 60 Peginterferon Alfa 2a 60 Elderly Patients 60 Metastatic Melanoma 60 CYP#A# substrate 60 plus dacarbazine 60 CYP#A# isoenzyme 60 R lenalidomide 60 Heterozygous Familial Hypercholesterolemia 60 Novel Oral 60 Albuferon TM 59 Phase IIb Trial 59 Study Evaluating 59 Shows Promise Against 59 Previously Untreated 59 Sipuleucel T 59 lenalidomide Revlimid R 59 Neovascular Age Related Macular 59 relapsed acute lymphoblastic 59 albiglutide currently 59 Phase 2b Trial 59 Severe Sepsis 59 Soft Tissue Sarcoma 59 Appears Safe 59 YOUR LOCAL ANIMAL SHELTER 59 Randomized Double Blind 59 Patients Treated With 59 Nebulized 59 Naive Patients 59 Second Pivotal Phase 59 ® bortezomib 59 relapsed refractory multiple myeloma 59 Initiates Phase II 59 CYP#A# CYP#D# 59 INSPIRE Trial Phase III 59 leukemia APL 59 Is Well Tolerated 59 Myeloma Patients 59 Peginterferon 59 Pemetrexed 59 VEGFR2 inhibitor 59 Treated Patients 59 Vincristine 59 metastatic colorectal carcinoma 59 humanized therapeutic 59 Vidaza ® 59 Completes Patient Enrollment 59 unresectable stage 59 Anthracycline 59 AAG geldanamycin analog 59 mitoxantrone plus 59 imatinib Gleevec ® 59 recurrent glioblastoma multiforme 59 advanced metastatic renal 59 Brentuximab Vedotin SGN 59 cyclophosphamide doxorubicin vincristine 59 Folfox 59 Crofelemer budesonide foam 59 influenza BCX# purine nucleoside 59 Inhaled Corticosteroids 59 Single Dose 59 Trial Evaluating 59 Leukemias 59 Tyrosine Kinase Inhibitors 59 Treatment Naive Patients 59 develop HBV reactivation 59 D aspartate NMDA receptor 59 Slow Progression 59 Myelodysplastic Syndrome MDS 59 Advanced Colorectal Cancer 59 Hepatitis C Genotype 59 following fluoropyrimidine oxaliplatin 59 accompanying electrolyte abnormalities 59 certolizumab 59 approved incretin mimetic 59 previously untreated follicular 59 myelodysplastic myeloproliferative diseases 59 Ovitrelle R Serostim 58 ATRA IV 58 metastatic malignant 58 FOLFIRI alone 58 pharmacogenomic translational research 58 Myelofibrosis 58 interferon alpha IFN 58 Gastrointestinal Stromal Tumors 58 evaluating Xcytrin 58 Posaconazole 58 Demonstrates Efficacy 58 ara C 58 Randomized Double blind 58 metastatic pancreatic 58 complement inhibitor eculizumab 58 Combination Treatment 58 biliary tract cancer 58 C1 INH deficiency 58 receiving INTRON 58 Humanized Anti 58 undergoing elective percutaneous 58 Romidepsin 58 PEGINTRON REBETOL combination 58 adjuvant GIST 58 non splenectomized 58 erlotinib Tarceva ® 58 Treatment Shows Promise 58 Aeolus Pharmaceuticals Announces 58 Mylan Receives Approval 58 Antitumor Activity 58 See WARNINGS 58 Perifosine KRX 58 VELCADE melphalan 58 Capsulitis 58 Suppository Hydrocortisone Acetate Rectal 58 Dose Ranging 58 Long Term Efficacy 58 Multicenter Randomized Double 58 TM pralatrexate injection 58 Prolongs Survival 58 Resistant Hypertension 58 Gene Mutation Linked 58 Diabetic Foot Ulcer 58 Chronic lymphocytic leukemia 58 atypical Hemolytic Uremic Syndrome 58 FOLFOX6 chemotherapy regimen 58 known dihydropyrimidine dehydrogenase 58 Bosutinib 58 oropharyngeal candidiasis OPC 58 COPEGUS R 58 Initiate Phase 58 Shows Promising 58 Hormone Receptor Positive 58 interferon beta 1a infertility 58 ISTODAX ® 58 TNF Tumor Necrosis Factor 58 Annamycin 58 Investigational Treatment 58 biologic antibody 58 sunitinib Sutent ® 58 MEK Inhibitor 58 cell carcinoma RCC 58 cladribine Cladribine Tablets 58 ADVANCE ILLUMINATE 58 imatinib resistant 58 Pruvel TM 58 Drug Prevents 58 Phase III Trial 58 metastatic androgen independent 58 Peginterferon alfa 2b 58 Phase 2b Clinical Trial 58 Metastatic Colorectal Cancer 58 Adjunctive 58 Sevelamer 58 See CLINICAL PHARMACOLOGY 58 naïve HCV 58 ribavirin RBV 58 dasatinib Sprycel 58 Fungal Infections 58 severe oral mucositis 58 doxorubicin cyclophosphamide 58 Initiates Clinical Trial 58 By JENNIFER LEARN 58 Anti Tumor 58 lymphoid blast 58 Slows Progression 58 individualized cellular immunotherapy 58 Pharmacokinetics PK 58 estramustine 57 Transdermal Patch 57 Secondary Hyperparathyroidism 57 chronic myeloid 57 CIMZIA TM certolizumab pegol 57 Clot Busting 57 Demonstrates Sustained 57 taxane chemotherapy administered 57 NDA Submission 57 4mg/kg 57 Renal Impairment 57 Treatment Resistant 57 metastatic castration resistant 57 Clinical Trial Evaluating 57 triggers apoptosis programmed 57 CDK cyclin dependent 57 PROACT Phase 2 57 recurrent genital herpes 57 Known hypersensitivity 57 Treatment Experienced 57 SPEAR Study 57 candidates Azedra TM 57 Ribavirin causes 57 Achieves Primary Endpoint 57 Relapsed Refractory Aggressive 57 R roscovitine CDK cyclin 57 particularly SANCTURA XR 57 forodesine 57 intravesical infusion therapy 57 resistant hormone refractory 57 Advanced Prostate Cancer 57 Dose Finding 57 evaluating Actimmune 57 Pivotal Phase III 57 prostate cancer HRPC 57 Subgroup Analysis 57 Monotherapy 57 Completes Enrollment 57 dual endothelin receptor antagonist 57 irinotecan doxorubicin oxaliplatin paclitaxel 57 Sapacitabine 57 Hematology Molecular Pathology 57 sapacitabine CYC# 57 relapsed CLL 57 rituximab refractory 57 Cell Lymphoma 57 bone marrow reticulin deposition 57 Darinaparsin 57 Dose Escalation 57 Paclitaxel Carboplatin 57 cyclophosphamide methotrexate 57 non constipating irritable 57 treat atopic dermatitis 57 Kit CD# positive 57 Phase 2a Clinical Trial 57 ZOLINZA 57 Primary Hypercholesterolemia 57 oral calcitonin licensed 57 RCW Breast Cancer 57 Initiates Enrollment 57 arthritis PsA 57 oral vancomycin 57 Phase 2a Trial 57 Toxicities 57 Intracranial Aneurysms 57 cetuximab Erbitux R 57 Teva Provides Update 57 recurrent NSCLC 57 moderate hepatic impairment 57 progressive PsA 57 Refractory Angina 57 NASH Huntington 57 CEL SCI Phase III 57 Elagolix 57 Limb Ischemia 57 Callisto initiated 57 Bronchiectasis 57 Glufosfamide 57 Pediatric Patients 57 Omacetaxine 56 Chronic lymphocytic leukemia CLL 56 refractory colorectal cancer 56 Bone Metastases 56 Chronic Lymphocytic Leukemia CLL 56 Chronic Myelogenous Leukemia 56 Successfully Completes Phase 56 steroid refractory ulcerative 56 kidney urologic 56 Chronic Renal Failure 56 Randomized Phase 56 anthracycline taxane 56 INDUSTRY ASSESSMENTS 56 via intradermal injections 56 HER2 Positive 56 follicular lymphoma FL 56 personalized cellular immunotherapy 56 Desvenlafaxine Succinate 56 virus HCV protease inhibitor 56 chronic immune thrombocytopenic 56 acetonide FA 56 J Am Acad 56 PEGylated docetaxel 56 Unfractionated Heparin 56 Gel repository corticotropin injection 56 Controlled Trial 56 Autoimmune Disorders 56 neutropenia dehydration dyspnea 56 Capecitabine 56 interferon gamma 1b 56 refractory acute myeloid 56 sodium benzoate prescription 56 plus prednisone 56 hypothyroidism hyperglycemia hypotension arrhythmihemorrhagic colitis development 56 BCG refractory carcinoma 56 Alemtuzumab 56 treatment naive genotype 56 intravenous belinostat 56 Fluorouracil 56 non metastatic osteosarcoma 56 NS5B polymerase 56 TRANSDUR ® 56 Pegloticase 56 oncolytic virus therapies 56 invasive candidiasis 56 Patients Treated 56 Uterine Fibroid Embolization 56 Elestrin ® 56 Vitrasert R 56 Non Alcoholic Steatohepatitis 56 relapsed multiple myeloma 56 novel emulsion formulation 56 Trial Issue www.emagazine.com 56 Metastatic Renal Cell Carcinoma 56 Dementia Related Psychosis 56 alvespimycin 56 bevacizumab Avastin ® 56 oral nucleoside analogue 56 Adjuvant Chemotherapy 56 remission induction 56 Chronic Hepatitis C 56 First Patient Dosed 56 damage cirrhosis liver 56 irinotecan cisplatin 56 AVASTIN 56 Phase IIb Clinical Trial 56 LymphoStat B belimumab 56 fungoides 56 PEGINTRON TM 56 melphalan prednisone 56 Phase 2b Study 56 imatinib Gleevec 56 novel tubulin binding 56 Acute Myocardial Infarction 56 recombinant PSMA vaccine 56 investigational oral inhibitor 56 Placebo Controlled 56 EXJADE 56 Initiated Phase 56 FDA APPROVES 56 non thiazolidinedione TZD 56 Paroxysmal Atrial Fibrillation 56 unique alkylating agent 56 plus gemcitabine 56 Confirmatory Phase 56 leukemia CLL 56 Allergic Rhinitis 56 intravenous RSD# 56 sorafenib Nexavar ® 56 Aflibercept 56 comparing alemtuzumab 56 BRIM2 56 adriamycin 56 demonstrated antitumor activity 56 Tarceva TM 56 peripheral sensory neuropathy 56 atypical hemolytic uremic syndrome 56 Tyrosine Kinase Inhibitor 56 thalidomide Thalomid 56 advanced carcinoid 56 Treating Chronic 56 alefacept 56 evaluating mipomersen 56 metastatic hormone refractory 56 3 registrational trial 56 Telik Announces 56 II Clinical Trial 56 sarcoma melanoma 56 EGFR expressing mCRC 56 Alimentary Tract 56 Cyclophosphamide 56 Diabetic Macular Edema 56 recurrent malignant glioma 56 SinuNase TM 55 Platinol ® 55 PREZISTA r 55 CTA# Injection 55 Stereotactic Body Radiation Therapy 55 decompensated liver disease 55 Metastatic Pancreatic Cancer 55 Wafer polifeprosan 55 elderly myelodysplastic syndromes 55 Advanced Renal Cell 55 follicular non 55 carmustine 55 NEBIDO VANTAS SUPPRELIN LA 55 novel orally inhaled 55 Chronic Myelogenous Leukemia CML 55 THAT ARE DIFFICULT TO 55 Proc Am Soc 55 Reduces Risk 55 accumulate preferentially 55 Coadministration 55 Drug Shows Promise 55 severe hypersensitivity reactions 55 PEGylated Fab fragment 55 platinum refractory 55 neuropathy sparing 55 Initiates Phase III 55 Spinal Fractures 55 + Perifosine Evaluation 55 Stage IIB 55 cheilitis 55 FOLFOX6 55 NMIBC 55 solid tumors ZYBRESTAT 55 Lymphocytic 55 primary immunodeficiency PI 55 number NCT# ClinicalTrials.gov 55 Picoplatin Efficacy After 55 Prostate AdenoCarcinoma Treatment 55 mycosis fungoides 55 ribavirin therapy 55 refractory metastatic 55 investigational monoclonal antibody 55 HGS ETR2 55 Submits NDA 55 stage IIIB 55 PI3K/Akt pathway inhibitor 55 metastatic renal cell carcinoma 55 metastatic castrate resistant 55 Therapeutic Efficacy 55 CCX# B 55 Pralatrexate 55 Phase III Pivotal 55 GVAX ® 55 partial onset seizures 55 Ovarian Cancers 55 Chronic Lymphocytic Leukemia 55 AVN# Phase 55 metastatic malignant melanoma 55 treatment naïve genotype 55 gemcitabine Gemzar ® 55 administering VIVITROL 55 erythematosus 55 Dupuytren Disease 55 rALLy 55 Pivotal Trial 55 Refractory Peripheral T 55 recurrent metastatic 55 evaluating tivozanib 55 worsening thrombocytopenia 55 Receives Orphan Drug Designation 55 Glatiramer Acetate 55 Soyabean Ext Bulk 55 venous stasis ulcers 55 papillary renal cell carcinoma 55 Induction Therapy 55 Myelodysplastic Syndromes 55 herpetic keratitis 55 #mg/m# [001] 55 Oral Calcitonin 55 Submits Biologics License Application 55 MAGE A3 ASCI 55 limiting toxicity DLT 55 Heart Failure Patients 55 HBeAg negative 55 pediatric malignancies 55 Chronic Heart Failure 55 Atypical Hemolytic Uremic Syndrome 55 Hypertensive Patients 55 Antitumor activity 55 TTF Therapy 55 agonistic human 55 refractory CLL 55 Telik logo TELINTRA 55 Clinical Trial Results 55 folinic acid 55 Syncria R 55 Miscellaneous Applications 55 Pre Cancerous 55 refractory acute promyelocytic 55 Gabapentin GR TM 55 nab paclitaxel 55 Voreloxin 55 Dose Ranging Study 55 Decompensated Heart Failure 55 generation purine nucleoside 55 HDAC Inhibitor 55 Initiates Phase 55 logo HeartMate 55 novel chimeric natriuretic 55 Solid Malignancies 55 Unresectable 55 Seasonal Allergic Rhinitis 55 acute leukemias 55 doublet chemotherapy 55 Cloretazine 55 lymphoma CTCL 55 Restenosis 55 Advaxis Phase 55 folinic acid FA 55 EOquin TM phase 55 Randomised 55 Well Tolerated 55 OMP #R# 55 Prednisone Against Refractory 55 Recurrent Breast Cancer 55 Carcinomas 55 Partial Onset Seizures 55 PNP inhibitor 55 Phase IIa Clinical Trial 55 catheter occlusion 55 R bortezomib 54 BR.# 54 MKC# MT 54 Diabetic Patients 54 Reduces Pain 54 pharmacodynamic profiles 54 Natalizumab 54 Cannabinor 54 vinorelbine tartrate 54 corticotropin injection 54 Patients Suffering 54 Phase III Clinical Trial 54 Balloon Angioplasty 54 idarubicin 54 refractory CTCL 54 Intravitreal 54 Nesiritide 54 EnteroMedics proprietary neuroblocking technology 54 refractory SCLC 54 rheumatoid arthritis RA psoriatic 54 metastatic renal 54 Accelerated Partial Breast Irradiation 54 recurrent glioblastoma 54 RCW breast cancer 54 keloid scarring 54 Oncolytic Reovirus 54 relapsed AML 54 iobenguane 54 Efficacy Trial 54 asymptomatic metastatic 54 CML CP 54 metastatic colorectal 54 tumors GIST 54 Effectively Treats 54 Hodgkin lymphoma HL 54 CHOP chemotherapy 54 Gemzar ® 54 Patients Undergoing 54 pediatric Crohn disease 54 Non Responders 54 follicular Non Hodgkin 54 evaluating T DM1 54 Evoltra ® 54 Deforolimus 54 Diabetic Foot Ulcers 54 Preclinical Models 54 acute mania 54 eosinophilic asthma 54 invasive aspergillosis 54 Therapy Improves 54 MCyR 54 Investigational Oral 54 irinotecan chemotherapy 54 idiopathic thrombocytopenic purpura 54 ELADUR ™ 54 Non Invasive Treatment 54 low dose dexamethasone 54 colitis UC 54 oral prodrug 54 Hematological Cancers 54 potentially hepatotoxic 54 PINPOINT TM System 54 Shows Statistically Significant 54 cancer neuroendocrine tumor 54 Horizant ™ 54 Orthop Surg 54 Xenografts 54 orally administered inhibitor 54 Squamous Cell Carcinoma 54 novel antimitotic agent 54 Pivotal Study 54 Granted Orphan Drug 54 Panzem R NCD 54 Motesanib 54 HGS ETR1 mapatumumab 54 oral picoplatin 54 Custirsen 54 HER2 positive metastatic breast 54 NMT Medical Announces 54 Quinamed 54 superficial bladder cancer 54 IMPACT DCM 54 Phase Ib II 54 Prospective Randomized 54 mapatumumab 54 DOXIL 54 DMARDS 54 Hedgehog Pathway Inhibitor 54 oral rivaroxaban 54 ciclopirox PLEXION R 54 alkylating agent 54 Paraplatin ® carboplatin 54 CINQUIL 54 imetelstat GRN#L 54 Pharmacologic 54 Predict Response 54 Acute Promyelocytic Leukemia 54 receptor tyrosine kinase inhibitor 54 evaluate ZFP Therapeutic 54 pegylated interferons 54 albiglutide 54 Overactive Bladder OAB 54 small lymphocytic lymphoma 54 Liver Metastases 54 refractory 54 AGILECT R 54 EGFR tyrosine kinase inhibitor 54 minimally symptomatic 54 refractory ovarian cancer 54 Epratuzumab 54 cytogenetic responses 54 Phase #b/#a clinical 54 Cytarabine 54 XL# anticancer compounds 54 data management Clintrial 54 indolent lymphoma 54 EGFR mutation positive 54 Effect Pigments ELANTAS Electrical 54 Gleevec resistant 54 2 methoxyestradiol 54 delivers fluocinolone acetonide FA 54 Patient Enrollment 54 IMiDs R 54 Bortezomib 54 Endometrial Cancer 54 vinca alkaloid 54 heavily pretreated 54 Ibritumomab Tiuxetan 54 Novel Compound 54 osteolytic bone disease 54 Multicenter Randomized 54 Therapy Reduces 54 anthracyclines taxanes 54 relapsed refractory 54 PEGylated interferon beta 1a 54 Systemic Sclerosis 54 Amigal TM 54 Glioblastoma Multiforme 54 Safinamide 54 advanced hepatocellular carcinoma 54 hypoxia activated prodrug 54 chronic myelogenous leukemia CML 54 Onyx Pharmaceuticals Announces 54 recurrent GBM 54 CHOP cyclophosphamide doxorubicin vincristine 54 antiangiogenic therapy 54 lintuzumab SGN 54 endoscopic autofluorescence imaging 54 Seliciclib CYC# 54 Begins Dosing 54 Myocardial Infarction Study 54 CLL SLL 54 FOLOTYN ® 54 relapsed ALL 54 Non Ferrous Alloys 54 Metabolic Efficiency 54 Myelodysplastic Syndrome 54 R vitespen 54 Bone Grafting 54 Synta Announces 54 rituximab refractory follicular 54 purpura ITP 54 Presents Positive 54 tramiprosate Alzhemed TM 54 Sanofi Aventis Taxotere 54 Pulmonary Arterial Hypertension 54 Epothilone D 53 fistulizing Crohn disease 53 NicVAX TM 53 AKT inhibitor 53 MIVI III 53 Phase III PREGNANT PROCHIEVE 53 Randomized Study 53 Initiates Phase 2b 53 VFEND 53 Pruvel ™ prulifloxacin 53 dacarbazine DTIC 53 polycythemia vera essential thrombocythemia 53 class mGluR5 inhibitor 53 Adjuvant Therapy 53 Personalized Immunotherapy 53 rhIGF-I/rhIGFBP-3 53 Schizoaffective Disorder 53 Non Alcoholic Fatty 53 evaluating satraplatin 53 CIMZIA ™ 53 Clolar ® 53 Mouse Model 53 DATE HEREOF AND 53 evaluating satraplatin plus 53 Irinotecan 53 ® chorionic gonadotropin 53 refractory multiple myeloma 53 hyperplasia BPH 53 YONDELIS 53 FOLFIRI 53 Hepatocellular Carcinoma 53 Bevacizumab 53 tumor lysis syndrome 53 IMPDH inhibitor 53 PANVAC VF 53 Phase Ib Clinical Trial 53 Autologous Stem Cell Transplantation 53 dose escalation phase 53 unstable angina UA 53 HCV RESPOND 2 53 Anti Tumor Activity 53 dose escalation clinical 53 sevelamer hydrochloride 53 Luramist TM 53 INTEGRILIN R eptifibatide Injection 53 gastrointestinal stromal tumor GIST 53 Zalypsis 53 hepatocellular cancer 53 Initiate Clinical Trial 53 Empatic ™ 53 relapsed leukemia 53 tyrosine kinase inhibitor TKI 53 xanthine oxidase inhibitor 53 Advanced Solid Tumors 53 Ophena TM 53 FOSRENOL ® 53 nilotinib 53 metaglidasen 53 6 sulfatase 53 BEYONCE AND 53 Physician Insights 53 Rheumatoid Arthritis RA 53 bevacizumab Avastin R 53 5-FU/LV 53 Helicobacter pylori eradication 53 Hepatocellular Carcinoma HCC 53 LHRH receptor positive 53 acute myelogenous leukemia AML 53 Tumor Response 53 cutaneous T cell 53 mCRC patients 53 hormone LHRH antagonist 53 Successfully Treats 53 VIVITROL ® 53 diagnosed glioblastoma multiforme 53 post herpetic neuralgia PHN 53 trastuzumab Herceptin R 53 fluorouracil 53 External Beam 53 unresectable locally advanced 53 refractory myeloma 53 VICTOR E1 53 VICTOR E3 53 acute myeloid 53 daunorubicin 53 hepatorenal syndrome 53 TACI Ig 53 refractory Hodgkin 53 induced macular edema 53 R sorafenib tablets 53 Knee Osteoarthritis 53 Acute Myelogenous Leukemia AML 53 Hepatocellular 53 Archexin 53 androgen independent 53 OMNARIS HFA 53 Fibromyalgia Syndrome 53 Sezary syndrome 53 Basal Cell Carcinoma 53 haematologic 53 huN# DM1 53 Central Retinal Vein 53 Adenoviral 53 ZACTIMA 53 candidemia 53 refractory DLBCL 53 bexarotene 53 Placebo controlled 53 EXECUTIVE SUMMARY II 53 Taxane 53 Protease Inhibitor 53 temsirolimus Torisel ® 53 pan HDAC inhibitor 53 Overactive Bladder 53 TRANSDUR ™ 53 hA# 53 autologous cellular immunotherapy 53 Tolerability 53 refractory AML 53 FDA Accepts 53 OAB overactive bladder 53 HP Acthar Gel repository 53 infantile spasms IS 53 Vicriviroc 53 monoclonal antibody conjugated 53 including eniluracil ADH 53 LHRH analogues 53 HCD# [002] 53 ulcerative colitis UC 53 docetaxel Taxotere R 53 idiopathic thrombocytopenic purpura ITP 53 PROVENGE ® 53 conventional DMARDs 53 Progenitor Cells 53 Polyethylene Glycol 53 evaluating ASA# 53 Clinical Efficacy 53 pegylated liposomal doxorubicin 53 JAK2 Inhibitor 53 ThermoDox R 53 glioblastoma multiforme GBM 53 Enrolling Patients 53 FluCAM 53 Newly Diagnosed 53 Mitoxantrone 53 #I TM# 53 sunitinib malate 53 cisplatin chemotherapy 53 PsA ulcerative colitis 53 interferon ribavirin 53 Postmenopausal Women 53 primidone 53 Hemispherx flagship products 53 REUNITE FOR 53 MYLOTARG 53 ovarian esophageal 53 Vascular Disrupting Agent 53 Pivotal Phase II 53 Stromal Cells 53 follicular lymphomas 53 ENESTnd 53 weekly subcutaneous injections 52 Statistically Significant 52 renal failure interstitial lung 52 Lenalidomide 52 fludarabine cyclophosphamide 52 REVIVE Diabetes 52 Navelbine ® 52 RISKS UNCERTAINTIES AND ASSUMPTIONS 52 Completes Dosing 52 Antiangiogenic 52 anthracycline containing 52 plus ribavirin 52 Idiopathic Pulmonary Fibrosis 52 Gliadel R 52 Attenuates 52 Orally Active 52 IIa Clinical Trial 52 evaluating pirfenidone 52 sorafenib Nexavar 52 Hypertrophy 52 trastuzumab Herceptin ® 52 docetaxel chemotherapy 52 receiving highly emetogenic 52 Drug Candidate 52 Commences Phase 52 velafermin 52 dasatinib 52 antibody MAb 52 ALN VSP Phase 52 achieve sustained virologic 52 dacarbazine 52 dimebon latrepirdine 52 Sudhir Agrawal D.Phil 52 Microplasmin 52 comparing XIENCE V 52 serum phosphorous 52 Amrubicin 52 Vertebral Compression Fractures 52 Immunotherapeutic 52 ARCALYST 52 phase III isavuconazole 52 icatibant 52 oral deforolimus 52 GRNOPC1 contains 52 pharmacologically active isomer 52 Recombinant Human 52 Intravenous palifosfamide 52 Testosterone MDTS ® 52 Gleevec imatinib mesylate 52 corticosteroid therapy 52 tiuxetan 52 Placebo Controlled Study 52 Rituxan rituximab 52 Diabetic Nephropathy 52 malignant mesothelioma Alfacell 52 cisplatin carboplatin 52 stage IIIA 52 Namenda Memantine HCl 52 EMD # 52 Papillary 52 fallopian tube carcinoma 52 GOUT